Andrew J. Schwab - 23 Feb 2023 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: ELVN
Reported as of: 23 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Apr 2023, 20:22:08 UTC
Prior SEC filing: 07 Dec 2021
Next SEC filing: 22 Aug 2023
Source filing: View source filing
Reporting owner signature: /s/ Ben Hohl, by power of attorney

Key filing fact

Andrew J. Schwab filed Form 4 for Enliven Therapeutics, Inc. (ELVN) on 06 Apr 2023.

Key facts

This page summarizes Andrew J. Schwab's Form 4 filing for Enliven Therapeutics, Inc. (ELVN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Apr 2023, 20:22.

Change

Previous filing in this sequence was filed on 07 Dec 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELVN transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +27,567
Change %
Price: $0.000000
Shares after: 27,567
Date: 23 Feb 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,567
Exercise price: $25.28
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/36th of the shares subject to the option will vest on March 23, 2023 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.